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Abstract
Chitosan (CS), a polysaccharide derived from chitin, the second most abundant polysaccharide, is widely
used in the medical world because of its natural and nontoxic properties and its innate ability for
antibacterial and hemostasis effects. In this study, the novel composites containing CS and cellulose
(CEL) (i.e., [CEL + CS]), which we have previously synthesized using a green and totally recyclable
method, were investigated for their antimicrobial activity, absorption of anticoagulated whole blood,
anti‐inflammatory activity through the reduction of tumor necrosis factor‐α (TNF‐α) and interleukin‐6
(IL‐6), and the biocompatibility with human fibroblasts. The [CEL + CS] composites were found to inhibit
the growth of both Gram positive and negative micro‐organisms. For examples, the regenerated 100%
lyophilized chitosan material was found to reduce growth of Escherichia coli (ATCC 8739 and vancomycin
resistant Enterococcus faecalis (ATCC 51299) by 78, 36, and 64%, respectively. The composites are
nontoxic to fibroblasts; that is, fibroblasts, which are critical to the formation of connective tissue matrix
were found to grow and proliferate in the presence of the composites. They effectively absorb blood,
and at the same rate and volume as commercially available wound dressings. The composites, in both
air‐dried and lyophilized forms, significantly inhibit the production of TNF‐α and IL‐6 by stimulated
macrophages. These results clearly indicate that the biodegradable, biocompatible and nontoxic
[CEL + CS] composites, particularly those dried by lyophilizing, can be effectively used as a material in
wound dressings. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 1199–
1206, 2014.

INTRODUCTION
Chitosan (CS), a linear polysaccharide derived from the N‐deacetylation of chitin, which is the second
most abundant polysaccharide, is known to possess unique properties including wound healing,
hemostasis, antibacterial activity, and is an effective drug carrier.1-9 These unique properties of CS work
in concert to synergistically influence three of the four phases of wound healing. In the coagulation
phase, the hemostatic effect of CS stops hemorrhage, which is generally more of a problem in acute
than chronic wounds. For wound healing to occur, all cells involved in the coagulation, inflammatory,
and proliferative phases survive in a moist environment. In a dehydrated or desiccated milieu cells die if
they dry. CS maintains cellular and tissue viability through its ability to keep the wound moist. Chronic
wounds such as ulcerations caused by venous and arterial insufficiency of the lower extremities,
pressure ulcers, and wounds that commonly occur from neuropathy and/or compromised blood
perfusion in the diabetic foot, generally are inhibited from healing owing to persistent bacterial bio‐
burdens during the inflammatory and proliferative phases. Since CS has excellent antimicrobial
properties, healing of these wounds will occur over more predictable time frames.
Chitosan is known to have the ability to deliver drugs. CS has the capability to encapsulate, stabilize, and
deliver drugs that enhance connective tissue matrix growth (i.e., granulation tissue formation) during
the proliferative phase of healing. Unfortunately, in spite of its clear advantages, there are drawbacks,
which limit applications of current chitosan‐based dressing products. For example, it is not possible to
dissolve CS in organic solvents because it has a rigid crystalline structure due to intra‐ and inter‐
molecular hydrogen bonds.10-12 As a consequence, an acid such as acetic acid is required to break
hydrogen bonds to facilitate dissolution. Subsequent neutralization with a base solution is then needed.
Such a procedure is not only costly and time consuming, but also may lead to acid induced changes in
the structure of CS.13, 14 Furthermore, CS has rather poor rheological properties and will undergo

extensive swelling in water. This makes it structurally too weak to be used by itself in any application. To
increase the structural strength of CS products, attempts have been made to cross‐link chitosan chains
with a cross‐linking agent or convert its functional group through a chemical reaction. In fact, all current
CS‐based biochemical and medical devices are based on these methods.15-19 The rather complicated,
costly, and multi‐step process currently used, that is, it involves the use of environmentally harmful
chemicals and solvents and man‐made polymers to strengthen its structure, is not desirable as it may
inadvertently alter or remove its unique properties, making the CS‐based composite materials less
biocompatible and toxic. A new method, which can effectively dissolve CS not at high temperature by
strong acid/base but rather by recyclable “green” solvent and to improve the structural strength of CS
products not by chemical modification with synthetic chemicals and/or polymers but rather by use of
naturally occurring biopolymers such as cellulose (CEL), is particularly needed.
Recently, we have developed a new method, which can offer a solution for this problem.20In this
method, we exploited advantages of a simple ionic liquid, butyl methylimmidazolium chloride
(BMIm+Cl−), a green solvent,20 to develop an innovative, simple, pollution‐free method to dissolve not
only CS but also other polysaccharides including CEL without using any acid or base, thereby avoiding
any possible chemical or physical changes. Secondly, we used only naturally occurring biopolymers, such
as CEL, as support materials to strengthen structure and expand utilities while keeping the
biodegradable, biocompatible and anti‐infective, and drug carrier properties of CS‐based materials
intact. Using this method, we have successfully synthesized composite materials containing CEL and CS
with different compositions.20 Preliminary results show that the composite materials obtained have
combined advantages of their components, namely superior chemical stability and mechanical stability
(from CEL) and excellent antimicrobial properties (from CS). The [CEL + CS] composite materials inhibit
growth of a wider range of bacteria than other CS‐based materials prepared by conventional methods.
Specifically, we found that over a 24 h period, the [CEL + CS] composite materials substantially inhibited
growth of bacteria such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant
Enterococcus (VRE), Staphylococcus aureus, and Escherichia coli.20
To evaluate the suitability of these novel [CEL + CS] composites for use as wound dressing material, we
systematically investigated their antimicrobial activity, ability to absorb anti‐coagulated whole blood,
anti‐inflammatory activity through the reduction of tumor necrosis factor‐α (TNF‐α) and interlukin‐6 (IL‐
6), and their biocompatibility with human fibroblasts. The results of our investigation are reported
herein.

MATERIALS AND METHODS
Materials

The preparation and complete characterization of the [CEL + CS] composite materials used in this study
was described in our previous publication.20 Minimal essential medium (MEM), 10% Fetal Bovine Serum
(FBS), and gentamicin were obtained from Atlanta Biologicals, Lawrenceville, GA. CellTiter 96® aqueous
non‐radioactive cell proliferation assay was obtained from Promega, Madison, WI. One Percent
Penicillin–Streptomycin and phorbol 12‐myristate 13‐acetate (PMA) were obtained from VWR, Radnor,
PA. The enzyme‐linked immunosorbent assay (ELISA) kit was from R&D Systems, Minneapolis, MN and
was used according to the manufacturer's instructions. Images of the fibroblasts and macrophages were
taken with an Olympus microscopic camera using CellSens Imaging Software (Olympus, Center Valley,

PA). Kendall – Curity AMD gauze sponges, 8 and 12 ply (Covidien, Mansfield, MA), Promogran matrix
wound dressing (Johnson & Johnson, New Brunswick, NJ), Aquacel and DuoDERM CGF (ConvaTec,
Princeton, NJ), Allevyn adhesive (Smith + Nephew, Andover, MA) are wound dressing that were
purchased commercially.

Bactericidal activity

Bacterial killing assays were performed in the presence and absence of the composites with varying
concentrations of CS and CEL. The bacterial strains used in this protocol included Escherichia coli (ATCC
8739), Staphylococcus aureus (ATCC 25923), methicillin resistant S. aureus (ATCC 33591), and
vancomycin resistant Enterococcus faecalis (ATCC 51299). The strains were maintained on blood agar at
4°C. According to a modified protocol from Pinto et al.,21 bacterial cells were grown in nutrient broth for
18–20 h at 37°C with agitation. The cells were diluted in fresh medium and incubated for 24 h at 37°C in
the presence of the composites. Serial dilutions of the bacteria were plated onto nutrient agar and
incubated for 24 h. Bacterial colony forming units (CFUs) were quantified and compared to bacteria
grown in the absence of composites.

Blood absorption

The capability of the commercially available wound dressings [Figure 1(C)] and [CEL + CS] composites to
absorb blood and the rate of absorption were examined using the procedure reported by Terrill et
al.22 In brief, each type of composite or dressing was premeasured and preweighed before testing. The
composites or the dressing materials were then placed in a square petri dish with approximately 30 mL
of whole blood donated by the Zablocki VA Medical Center, Milwaukee, WI. The dishes were incubated
at 37°C. Before being weighed, the material was suspended above the dish for 30 s to release all
unabsorbed blood. The composites and dressings were weighed at 30 min and 24 h. The amount of
blood absorbed was then calculated as g/100 cm2.

Figure 1 Comparison of blood absorbed over time by air‐dried and lyophilized [CEL + CS] composites (A and B) and
commercially available wound dressing materials (C) at 30 min (red) and 24 h (blue). At least three independent
experiments were performed. [Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com.]

Fibroblast adherence and growth

The adherence and growth of fibroblasts in the presence of the [CEL + CS] composites were assessed
with modifications from Kloth et al.23 Essentially, human fibroblasts (ATCC CRL‐2522) were grown in
minimal essential medium (MEM) supplemented with 10% FBS and 0.25 mg/mL gentamicin according to
ATCC guidelines until at least the 2nd passage. Cells were seeded into the wells containing membrane
composites at a concentration of 8 × 104cells/mL per well. Cells were imaged by an Olympus microscope
camera using CellSens Imaging Software.

Viability assay

The proliferation of fibroblasts was assessed by the CellTiter 96® aqueous non‐radioactive cell
proliferation assay by the reduction of MTS [3‐(4,5‐dimethylthiazol‐2‐yl)−5‐(3‐
carboxymethoxyphenyl)−2‐(4‐sulfophenyl)−2H‐tetrazolium] into a formazan product. The protocol was
modified according to Silva et al. In brief, the MTS reagent was added to each well in a 5:1 ratio with the
fresh noncolored culture medium.24 The cells were incubated at standard culture conditions for 4 h and
the optical density (490 nm) was measured.

Cell culture

The human monocytic cell line THP‐1 (ATCC TIB‐202) was cultured in RPMI‐1640 medium supplemented
with 10% FBS and 1% Penicillin–Streptomycin. Stimulation and differentiation of monocytes to
macrophages was performed by adding 0.2 µM phorbol 12‐myristate 13‐acetate (PMA) to the medium.
The cell line was maintained under 5% CO2 humidified atmospheric conditions in a 37°C incubator.

Cytokine measurement

The cultured monocytes were grown and diluted to a concentration of 5 × 105 cells/mL. A 24‐well tissue
culture plate was seeded with 1.6 mL of cells and [CEL + CS] composites were added to appropriate
wells. TNF‐α and interleukin‐6 (IL‐6) levels were measured and data analyzed using an ELISA kit
according to manufacturer's instructions. Images of the macrophages were taken with an Olympus
microscopic camera using CellSens Imaging Software.

Statistical analysis

Statistics on data were performed with Microsoft Excel and StatPlus® software. Data are
presented ± standard error of the mean. A p value of ≤ 0.05 was considered significant.

RESULTS AND DISCUSSION
Chitosan has proven to have efficient antimicrobial activity.24-26 It has been widely used in the food and
agricultural industries and in wound dressings because of its characteristic antibacterial activity toward
both Gram positive and Gram negative organisms.27 To assess the antimicrobial abilities of the [CEL + CS]
composites, bacteria were grown in the presence of the composites and then plated out onto growth
agar and measured by the amount of colonies formed compared to a standard growth control. The
results for the percent growth reduction of the different composites are shown in Table 1. It is evident
that there is bactericidal activity with the lyophilized 100% chitosan sample (Chitosan L) for all the
bacteria except for S. aureus, with the greatest effect on E. coli and VRE. The 50% composite had the
greatest effect on S. aureus. Even though there was a bactericidal effect on MRSA with lyophilized 100%
CS, 50%, and 29% [CS + CEL] composites; the standard deviations associated with each growth reduction

value was relatively high. It seems, therefore, that statistically, there was no significant growth reduction
among all of the composites for MRSA. Since errors associated with results obtained for effect on
P. aeruginosa are relatively large the results are inconclusive. This may be due to the fact that it was
found that the inner surface of the test tube used in this assay was found to be coated with biofilm. This
is hardly surprising because this microbe is known to be a strong producer of biofilms, and as described
below, the chitosan composites were found to have no effect on bacterial biofilms.
Table 1. Percent Growth Reduction of Bacteria Growth in the Presence of Chitosan Composites
100% Chitosan 100% Chitosan (L) 50% Chitosan 29% Chitosan
S. aureus
35 (±30)
−5.3 (±76)
70 (±11)
54 (±38)
MRSA
−0.4 (±1)
36 (±42)
2 (±21)
14 (±14)
VRE
−21 (±65)
64 (±35)
30 (±26)
38 (±19)
E. coli
15 (±34)
78 (±17)
9 (±23)
39 (±31)
P. aeruginosa −41 (±6.3)
42.5 (±71)
−218 (±22)
80 (±52)
The bacteria used in this study were selected because they were found to have the highest morbidity
and mortality associated with wound infections. Similar effect was also observed by Burkatovskaya and
co‐workers who reported that Chitosan acetate has greater effect against micro‐organisms both in
vitro and in a mouse wound model than other types of nonchitosan wound treatments.27-29 Ignatova et
al.30, 31 demonstrated that electrospun mats of quarternized chitosan killed bacteria, especially S.
aureus and E. coli within 2 h. Modified chitosan material, such as quarternized or those supplemented
with silver nanoparticles were reported to have more of an effect with micro‐organisms than chitosan
alone.21, 30, 31 Cai et al.32 showed an inhibition of E. coli growth, but not with S. aureus with a chitosan/silk
fibroin composite. Also, chitosan–dextran hydrogel composite has shown to exhibit antimicrobial
activity against Staphylococcus, Streptococcus, Clostridium, and E. coli,33 and Wu et al.34 showed a
chitosan dose dependent bacteriostatic effect on S. aureus and E. coli with their chitosan/cellulose blend
of composites.
In this study, we used chitosan composites in their natural state or in a composite with cellulose.
Modifications to chitosan material can be expensive, potentially toxic, and complicated to produce. To
be able to use chitosan in its natural state in a wound dressing, the benefits with respect to
biodegradability, toxicity, and production would be advantageous. Results obtained in this study clearly
indicate that the novel [CEL + CS] composite previously synthesized by us can effectively kill both Gram
positive (S. aureus and VRE) and Gram negative (E. coli and P. aeruginosa) bacteria over a period of 24 h.
Clearly, their antimicrobial activities are superior to those reported for composites made from chitosan
and man‐made polymers. Bacteriostatic and bactericidal properties are known to be important for
wound healing applications in preventing infection and even possible sepsis. These effects of the
chitosan composites on the wound pathogens illustrate their great potential as components in wound
dressings.
Subsequently, bacterial biofilms were assessed for a change in metabolic activity in the presence of the
chitosan material. It was found that after 24 h, the chitosan composites did not decrease the metabolic
activity compared to the (no‐chitosan) control biofilm (data not shown). It is hardly surprising to observe
lack of effect of the chitosan composites on biofilms because biofilms are known to envelop bacteria
with a polymeric matrix that prevents topical antibiotics and antiseptic agents from reaching the

infecting microbes.35 In fact, currently, all available broad spectrum antimicrobial agents that are
typically used on chronic wounds (e.g., sodium hypochlorite, cadexomer iodine, chlorhexidine, and
hydrogen peroxide) are not able to eradicate biofilms. Of interest is the recent report to indicate that
low intensity electric fields can completely override the inherent resistance of biofilm bacteria to
biocides and antibiotics. Experiments are now in progress to investigate this possibility.36
An ideal wound dressing material should maintain a delicate balance of absorption of fluids with the
ability to maintain a moist healing environment for proper tissue repair. The results obtained for
absorption of whole blood by air‐dried [CEL + CS] composites, lyophilized [CEL + CS] composites and
commercial dressings including Allevyn, Aquacel, Curity Gauze, Promogram, and DuoDerm over 30 min
and 24 h are shown in Figure 1(A–C), respectively. Compared to the other fiber‐based commercial
dressings, the present lyophilized [CEL + CS] composites have comparable levels of whole blood
absorption. In this study, whole blood was used instead of saline or prepared artificial transudate or
exudate material because it was previously found that the types of dressings, including foam, alginates,
gauze, hydrocolloids, and collagen absorb whole blood different from the other two artificial media.37 To
be more consistent with the physiological environment of a wound, we chose to examine the
absorptivity with whole blood. Terrill et al. also stated that a dressing that absorbs over 35 g/100
cm2 would be good for bleeding wounds.22
It is evident from Figure 1(A,B) that for all compositions, [CEL + CS] composites dried by lyophilizing
absorb relatively higher amount of blood compared to those air‐dried. Depending on composition,
lyophilized composites absorb at least 2–6× more blood compared to those by air‐dried composites.
Absorption amount by the air‐dried [CEL + CS] composites are comparable to the commercial
nonlyophilized dressings (Promogram and DuoDerm), all between 2 and 7 g/100 cm2. The lyophilized
[CEL + CS] composites showed comparable results for absorption over time to the commonly used
lyophilized dressings such as gauze, Aquacel, and Allevyn. Moreover, we found that the absorption
values of the composites approached the absorption amounts of the standard gauze and the Allevyn
dressing, which may be used for moderate to heavily bleeding wounds. In particular, 29, 40, and 50%
chitosan lyophilized materials are more absorptive than the Aquacel dressing materials. It is known that
the fibrous make‐up of gauze can lead to an increase of inflammation and on removal can cause trauma
to the wound viable tissues with associated pain.
Of particular importance is the observation that all of the lyophilized [CEL:CS] composites did have rapid
absorption rates, such that the amount of blood absorbed at 30 min and 24 h did not differ greatly. In
contrast, the air‐dried [CEL:CS] composites did absorb at a slower rate. This finding is not insignificant
and may be descriptive to what type of wound would benefit by a specific composite.
The results presented clearly indicate that the blood absorption capability of the [CEL + CS] composites is
comparable to those of commercial dressings, and that the composites have ability to maintain moisture
balance for wound healing. Such ability is one of the most important factors in the development of a
biodegradable and biocompatible novel wound dressing material.
The [CEL + CS] composites developed for wound dressing material must help to promote wound healing
by creating a moist microenvironment for proper tissue regeneration. The presence of fibroblasts is
critical for healing and the interaction of the fibroblasts with the composites must promote cellular and
collagen proliferation. Previous reports have shown that chitosan materials are nontoxic to fibroblasts.38-

It is expected that chitosan composites can play a role in physiological regeneration of tissue during
the wound healing process.
40

In this study we analyzed the morphology and the proliferation capabilities of adherent fibroblasts by
examining morphology microscopically. Results of the morphological analysis in the short term (3 days)
and long term (7 days) are shown in Figures 2 and 3, respectively. Adherent fibroblasts were seen in
wells after 3 days compared to the control well. The 7 day images show healthy fibroblasts in wells
containing all chitosan composites. The adherent cells in 0, 29, 40, 100, and 100% lyophilized (i.e.,
100%L) showed a typical morphology of an elongated body and more cells than the other wells. As
shown, compared to the control well, the chitosan composites did exhibit proliferation. The data in this
study supports the use of the modified chitosan composites and the continued development of the
material for proper scaffolding during wound healing.

Figure 2 Images (40×) of human fibroblast in the presence and absence of [CEL + CS] composites for 3 days. Only
one composite is lyophilized (100%L); the rest are all air‐dried. The experiment was performed in duplicate.

Figure 3 Images (40×) of human fibroblast in the presence and absence of [CEL + CS] composites for 7 days. Only
one composite is lyophilized (100%L), the rest are all air‐dried. The experiment was performed in duplicate.

Proliferation and viability of fibroblasts (Figure 4) in the presence and absence of chitosan composites
were measured by the MTS assay (see Materials). Similar to Fakhry et al.,41 our study shows the
proliferation of fibroblasts over time (from 3 to 7 days) and in the presence of chitosan there is a slowing
of growth and proliferation although the cells still maintain the proper morphology. These results are in
contrast to previous studies with modified chitosan material showing a direct correlation between time
of incubation and amount of proliferation.32, 40 Mori et al.42 theorized that materials with higher
amounts of chitosan can inhibit growth of fibroblasts indirectly. Chitosan that can bind proteins and the
fetal bovine serum used in the culture medium may be causing the caustic effect on the fibroblasts. Silva
et al.40 more recently showed the ability to increase the host response of proliferation by fibroblasts
with argon and nitrogen gases in plasma surface modification to their chitosan composites.

Figure 4 Fibroblast viability was measured at 30 min (blue bars) and 24 h (red bars) by the conversion of MTS to a
formazan product in the presence of active metabolic enzymes (see text for detailed information). The fibroblast
metabolic activity was tested in the presence and absence of [CEL + CS] chitosan composites. Only one composite
is lyophilized (100%L), the rest are all air‐dried. The experiments were performed in duplicate. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]

The wound environment requires a proper balance between a multitude of factors including blood
clotting, cellular survival, and tissue repair. Another benefit to proper wound healing is for the dressing
material to possess anti‐inflammatory activity, since proinflammatory cytokines (TNF‐α and IL‐6) are
primary contributors to the inflammation associated with chronic wounds, which stalls and prevents
them from proceeding into the proliferative phase of tissue regeneration. Consequently it is important
to assess the biocompatibility of potential dressing materials. Accordingly, the [CEL + CS] composites
were tested for anti‐inflammatory effects on macrophage derived TNF‐α and IL‐6. Results obtained,
shown as images for TNF‐α (Figure 5) and quantitative for both TNF‐α and IL‐6 [Figure 6(A,B)] indicate
that, similar to fibroblasts, monocytes were viable and able to differentiate into macrophages in the
presence of the chitosan composites especially the 100% and 100%L material.

Figure 5 Images of macrophages (40×) in the presence and absence of [CEL + CS] composites. Only one composite
is lyophilized (100%L), the rest are all air‐dried. Monocytes were stimulated to become macrophages with PMA
(see text for detailed information). The macrophages were cultured in the presence and absence of the [CEL + CS]
composites. The experiments were performed in duplicate.

Figure 6 Production of (A) TNF‐α and (B) IL‐6 by macrophages in the presence and absence of [CEL + CS]
composites. Macrophages were cultured in the presence and absence of [CEL + CS] composites. Only one
composite is lyophilized (100%L), the rest are all air‐dried. The amount of TNF‐α and IL‐6 produced by the
macrophages was quantified by ELISA.

Macrophages play an important role in our innate immunity to foreign substances, but can also mediate
many responses when there is injury to tissue. These cells can phagocytize or engulf micro‐organisms
and cellular debris. They respond to tissue damage and infectious micro‐organisms by phagocytosis and
the release of chemical mediators known as cytokines. TNF‐α and IL‐6, proinflammatory cytokines are
released and can help to regulate the immune response, but it can also lead to tissue damage to the
host. Proinflammatory cytokines are upregulated during wound healing and regeneration. Mori et
al.43 showed in a TNF receptor deficient wound mouse model that the time of healing and tissue
regeneration was increased significantly. Their study concluded the need for an anti‐inflammatory
environment for accelerated wound healing. It has been noted that the over production of IL‐6 has been
associated with an increase in the production of scarring during wound healing.44
The proinflammatory cytokines can be used as biomarkers for the proper differentiation of monocyte to
macrophage and the inflammatory response of the macrophage.45-47 TNF‐α and IL‐6 were measured
quantitatively to assess the inflammatory response in the presence of the chitosan composites and the
results are shown in Figure 6(A,B), respectively. As shown, compared to the control macrophages (Cells
alone + PMA), the 0, 29, and 40% chitosan composites showed no significant change in the amount of
TNF‐α secreted within a 3 day period. The TNF‐α concentrations of 100% and 100% lyophilized chitosan
composites were significantly lower, p = 0.05 and 0.01, respectively, than control showing a potential
anti‐inflammatory effect. The IL‐6 levels were reduced considerable in the presence of 67, 100, and
100% lyophilized chitosan material. This anti‐inflammatory effect with chitosan has been shown
previously.47, 48 Oliveira et al.,49 showed that when chitosan was exposed to monocytes as the sole

stimulant, after 10 days of incubation, the cytokine levels, including TNF‐α and IL‐6, reached anti‐
inflammatory levels. Those results correlate with our study clearly indicate the anti‐inflammatory effects
of [CEL + CS] composites on PMA derived macrophages.
In summary, we have successfully demonstrated that the novel [CEL + CS] composites, which we have
previously synthesized using a green and totally recyclable method, possess all properties needed to be
used effectively as a wound dressing. Specifically, the composites are antibacterial, hemostatic,
biocompatible, good absorbent for anticoagulated whole blood, and are able to maintain moisture
balance for wound healing. For example, the composites were found to inhibit the growth of both Gram
positive and negative micro‐organisms (including Escherichia coli (ATCC 8739), Staphylococcus
aureus (ATCC 25923), methicillin resistant S. aureus (ATCC 33591), and vancomycin
resistant Enterococcus faecalis(ATCC 51299)). They are nontoxic to fibroblasts, namely fibroblasts were
found to grow and proliferate in the presence of the composites. They effectively absorb blood, and at
the same rate and volume as commercially available wound dressings. The composites, in both air‐dried
and lyophilized forms, significantly inhibit the production of TNF‐α and IL‐6 by stimulated macrophages.
Experiments are now in progress to evaluate wound dressing based on the composites.

ACKNOWLEDGMENTS
The authors are grateful to Ms. Anna J Frazier for her competent technical assistance.

REFERENCES
1 Dai, T, Tegos, GP, Barkatovskaya, M, Castano, AP, Hamblin, MR. Chitosan acetate bandage as a topical
antimicrobial dressing for infected burns. Antimicrob Agents Chemother 2009; 53: 393– 400.
2 Bordenave, N, Grelier, S, Coma, V. Hydrophobization and antimicrobial activity of chitosan and paper‐
based packaging materials. Biomacromolecules 2010; 11: 88– 96.
3 Rabea, EI, Badawy, M, Stevens, CV, Smagghe, G, Steurbaut, W. Chitosan as antimicrobial agent:
Applications and mode of action. Biomacromolecules 2003; 4: 1457– 1465.
4 Altiok, D, Altiok, E, Tihminlioglu, F. Physical, antibacterial and antioxidant properties of chitosan films
incorporated with thyme oil for potential wound healing applications. J Mater Sci Mater
Med2010; 21: 2227– 2236.
5 Burkatovskaya, M, Tegos, GP, Swietlik, E, Demidova, TN, Castano, AP, Hamblin, MR. Use of chitosan
bandage to prevent fatal infections developing from highly contaminated wounds in
mice. Biomaterials 2006; 27: 4157– 4164.
6 Kiyozumi, T, Kanatani, Y, Ishihara, M, Saitoh, D, Shimizu, J, Yura, H, Suzuki, S, Okada, Y, Kikuchi,
M. Medium (DMEM/F12)‐containing chitosan hydrogel as adhesive and dressing in autologous
skin grafts and accelerator in the healing process. J Biomed Mater Res B 2006; 79B: 129– 136.
7 Jain, D, Banerjee, R. Comparison of ciprofloxacin hydrochloride‐loaded protein, lipid, and chitosan
nanoparticles for drug delivery. J Biomed Mater Res B 2008; 86: 105– 112.
8 Varshosaz, J, Tabbakhian, M, Salmani, Z. Designing of a thermosensitive chitosan/poloxamer in situ gel
for ocular delivery of ciprofloxacin. Open Drug Delivery J 2008; 2: 61– 70.
9 Naficy, S, Razal, JM, Spinks, GM, Wallace, GG. Modulated release of dexamethasone from chitosan‐
carbon nanotube films. Sens Actuators A 2009; 155: 120– 124.
10 Finkenstadt, VL, Millane, RP. Crystal structure of Valonia cellulose
1β. Macromolecules 1998; 31: 7776– 7783.

11 Augustine, AV, Hudson, SM, Cuculo, JA. Cellulose sources and exploitation. In: JF Kennedy, GO
Philipps, PA Williams, editors. Aspects of Cellulose Structure. New York: E. Horwood; 1990. p 59.
12 Dawsey, TR. Cellulosic polymers, blends and composites. In: RD Gilbert, editor. Water Soluble
Cellulose Derivative and Their Commercial Use. New York: Carl Hanser Verlag; 1994. p 157.
13 Cai, J, Liu, Y, Zhang, L. Dilute solution properties of cellulose in LiOH/urea aqueous system. J Polym Sci
B Pol Phys 2006; 44: 3093– 30105.
14 Fink, HP, Weigel, P, Purz, HJ, Ganster, J. Structure formation of regenerated cellulose materials from
NMMO‐ solutions. Prog Polym Sci 2001; 26: 1473– 1524.
15 Miao, J, Zhang, F, Takieddin, M, Mousa, S, Linhardt, RJ. Adsorption of doxorubicin on poly(methyl
methacrylate)‐chitosan‐heparin‐coated activated carbon beads. Langmuir 2012; 28: 4396– 4403.
16 McCarthy, SJ, Gregory, KW, Morgan, JW. Tissue dressing assemblies systems, and methods formed
from hydrophilic polymer sponge structures such as chitosan. WO Patent No. 062896, 2005.
17 El‐Mekawy, A, Hudson, S, El‐Baz, A, Hamza, H, El‐Halafawy, K. Preparation of chitosan films mixed
with superabsorbent polymer and evaluation of its haemostatic and antibacterial activities. J
Appl Polym Sci 2010; 116: 3489– 3496.
18 Sandoval, M, Albornoz, C, Munoz, S, Fica, M, Garcia‐Huidobro, I, Mertens, R, et al. Addition of
chitosan may improve the treatment efficacy of triple bandage and compression in the
treatment of venous leg ulcers. J Drugs Dermatol 2010; 10: 75– 80.
19 Jayakumar, R, Prabaharan, M, Sudheesh, PT, Nair, SV, Tamura, H. Biomaterials based on chitin and
chitosan in wound dressing applications. Biotech Adv 2011; 29: 322– 337.
20 Tran, CD, Duri, S, Harkins, A. Recycle synthesis, characterization and properties of polysaccharide
ecocomposite materials. J Biomed Mater Res A 2013; 101: 2248– 2257.
21 Pinto, RJB, Fernandes, SCM, Freire, CSR, Sadocco, P, Causio, J, eto, CP, Trindade, T.Antibacterial
activity of optically transparent nanocomposite films based on chitosan or its derivatives and
silver nanoparticles. Carbohydr Res 2012; 348: 77– 83.
22 Terrill, P, Sussman, G, Bailey, M. Absorption of blood by moist wound healing dressings. Prim
Intention 2003; 1: 7– 10.
23 Kloth, LC, Berman, JE, Laatsch, LJ, Kirchner, PA. Bactericidal and cytotoxic effects of chloramine‐T on
wound pathogens and human fibroblasts in vitro. Adv Skin Wound Care 2007; 20: 331– 345.
24 Rabea, EI, Badawy, MET, Stevens, CV, Smagghe, G, Steurbaut, W. Chitosan as antimicrobial agent:
Applications and mode of action. Biomacromolecules 2003; 4: 1457– 1465.
25 Kong, M, Chen, XG, Xing, K, Park, HJ. Antimicrobial properties of chitosan and mode of action: A state
of the art review. Int J Food Microbiol 2010; 144: 51– 63.
26 Jayakumar, R, Prabaharan, M, Sudheesh, PT, Nair, SV, Tamura, H. Biomaterials based on chitin and
chitosan in wound dressing applications. Biotech Adv 2011; 29: 322– 337.
27 Burkatovskaya, M, Tegos, GP, Swietlik, E, Demidova, TN, Castano, AP, Hamblin, MR. Use of chitosan
bandage to prevent fatal infections developing from highly contaminated wounds in
mice. Biomaterials 2006; 27: 4157– 4164.
28 Burkatovskaya, M, Castano, AP, Demidova‐Rice, TN, Tegos, GP, Hamblin, MR. Effect of chitosan
acetate bandage on wound healing in infected and noninfected wounds in mice. Wound Repair
Regen 2008; 16: 425– 431.
29 Dai, T, Tegos, GP, Burkatovskaya, M, Castano, AP, Hamblin, MR. Chitosan acetate bandage as a
topical antimicrobial dressing for infected burns. Antimicrob Agents
Chemother 2009; 53: 393– 400.

30 Ignatova, M, Starbova, K, Markova, N, Naolova, N, Rashkov, I. Electrospun nano‐fibre mats with
antibacterial properties from quarternized chitosan and poly(vinyl alcohol). Carbohydr
Res2006; 341: 2098– 2107.
31 Ignatova, M, Manolova, N, Rashkov, I. Novel antibacterial fibers of quarternized chitosan and
poly(vinyl pyrrolidine) prepared by electrospinning. Eur Polym J 2007; 43: 1112– 1122.
32 Cai, ZX, Mo, XM, Zhang, KH, Fan, LP, Yin, AL, He, CL, Wang, HS. Fabrication of chitosan/silk fibroin
composite nanofibers for wound‐dressing applications. Int J Mol Sci 2010; 11: 3529– 3539.
33 Aziz, MA, Cabral, JD, Brooks, HJ, Moratti, SC, Hanton, LR. Antimicrobial properties of a chitosan
dextran‐based hydrogel for surgical use. Antimicrob Agents Chemother 2012; 56: 280– 287.
34 Wu, YB, Yu, SH, Mi, FL, Wu, CW, Shyu, SS, Peng, CK, Chao, AC. Preparation and characterization on
mechanical and antibacterial properties of chitosan/cellulose blends. Carbohydr
Polym 2004; 57: 435– 440.
35 Spoering, AL, Lewis, K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar
resistance to killing by antimicrobials. J Bacteriol 2001; 183: 6746– 6751.
36 Costerton, JW, Ellis, B, Kan, L, Johnson, F, Khoury, AE. Mechanism of electrical enhancement of
efficacy of antibiotics in killing biofilm bacteria. Antimicrob Agents
Chemother 1994; 38: 2803– 2809.
37 Fulton, JA, Blasiole, KN, Cottingham, T, Tornero, M, Graves, M, Smith, LG, Mirza, S, Mostow,
EN.Wound dressing absorption: A comparative study. Adv Skin Wound Care 2012; 25: 315– 320.
38 Chatelet, C, Damour, O, Domard, A. Influence of the degree of acetylation on some biological
properties of chitosan films. Biomaterials 2001; 22: 261– 268.
39 Silva, SS, Santos, MI, Coutinho, OP, Mano, JF, Reis, RL. Physical properties and biocompatibility of
chitosan/soy blended membranes. J Mater Sci Mater Med 2005; 16: 575– 579.
40 Silva, SS, Luna, SM, Gomes, ME, Benesch, J, Pashkuleva, I, Mano, JF, Reis, RL. Plasma surface
modifications of chitosan membranes: Characterization and preliminary cell response
studies. Macromol Biosci 2008; 8: 568– 576.
41 Fakhry, A, Schneider, GB, Zaharias, R, Senel, S. Chitosan supports the initial attachment and spreading
of osteoblasts preferentially over fibroblasts. Biomaterials 2004; 25: 2075– 2079.
42 Mori, T, Okumura, M, Matsuura, M, Ueno, K, Tokura, S, Okamoto, Y, Minami, S, Fujinaga, T.Effects of
chitin and its derivatives on the proliferation and cytokine production of fibroblasts in
vitro. Biomaterials 1997; 18: 947– 951.
43 Mori, R, Kondo, T, Ohshima, T, Ishida, Y, Mukaida, N. Accelerated wound healing in tumor necrosis
factor receptor p55‐deficient mice with reduced leukocyte infiltration. FASEB
J 2002; 16: 963– 974.
44 Werner, S, Grose, R. Regulation of wound healing by growth factors and cytokines. Physiol
Rev2003; 83: 835– 870.
45 Anderson, JM. Biological responses to materials. Ann Rev Mater Res 2001; 31: 81– 110.
46 Anderson, JM, Rodriguez, A, Chang, DT. Foreign body reaction to biomaterials. Semin
Immunol2008; 20: 86– 100.
47 Xia, Z, Triffitt, JT. A review on macrophage responses to biomaterials. Biomed Mater 2006; 1: R1– R9.
48 Lee, HS, Stachelek, SJ, Tomczyk, N, Finley, MJ, Composto, RJ, Eckmann, DM. Correlating macrophage
morphology and cytokine production resulting from biomaterial contact. Soc Biomater 2012;
doi: 10.1002/jbm.a.34309.

49 Oliveira, MI, Santos, SG, Oliveira, MJ, Torres, AL, Barbosa, MA. Chitosan drives anti‐ inflammatory
macrophage polarisation and pro‐inflammatory dendritic cell stimulation. Eur Cells
Mater 2012; 24: 136– 153.

